SCHEMBL4585801

SCHEMBL4585801

O=c1cc(-c2ccccc2Cl)oc2c([C@@H]3CCNC[C@H]3CO)c(O)cc(O)c12

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK4 P11802 14/20 0.64
CDK1 P06493 14/20 0.64
CCND1 P24385 12/20 0.64
CCNB1 P14635 11/20 0.64
CDK2 P24941 10/20 0.64
CDK9 P50750 8/20 0.64
CCNB2 O95067 8/20 0.64
CCNB3 Q8WWL7 8/20 0.64
CCNT1 O60563 7/20 0.64
CCNA2 P20248 5/20 0.64
CCNE1 P24864 5/20 0.64
GSK3A P49840 4/20 0.64
CDK6 Q00534 4/20 0.64
CDK7 P50613 3/20 0.64
CCND3 P30281 3/20 0.64
CCNH P51946 2/20 0.64
MNAT1 P51948 2/20 0.64
MAPK15 Q8TD08 2/20 0.64
CAMKK2 Q96RR4 2/20 0.64
CCNA1 P78396 2/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7829623 1.00 CDK4 (0.64) CDK4CDK1CCND1CCNB1CDK2
Hydrochloric Acid SCHEMBL15636652 0.99 CDK4 (0.65) CDK4CDK1CCND1CCNB1CDK2
Hydrochloric Acid SCHEMBL4447778 0.99 CDK4 (0.65) CDK4CDK1CCND1CCNB1CDK2
SCHEMBL5735816 0.89 CDK4 (0.53) CDK4CDK1CCND1CCNB1CDK2
SCHEMBL23683032 0.88 CDK4 (0.75) CDK4CDK1CCND1CCNB1CDK2
SCHEMBL20181812 0.88 CDK4 (0.75) CDK4CDK1CCND1CCNB1CDK2
SCHEMBL24669074 0.87 CDK4 (0.74) CDK4CDK1CCND1CCNB1CDK2
SCHEMBL22580714 0.85 CDK4 (0.67) CDK4CDK1CCND1CCNB1CDK2
SCHEMBL8821026 0.83 CDK4 (0.60) CDK4CDK1CCND1CCNB1CDK2
SCHEMBL16722415 0.82 CDK4 (0.64) CDK4CDK1CCND1CCNB1CDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2018049233-A9 INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR 4 IN COMBINATION WITH CYCLIN-DEPENDENT KINASE INHIBITORS STRANSKY NICOLAS (US) 2018-07-12 WO claimed
WO-2018049233-A1 INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR IN COMBINATION WITH CYCLIN-DEPENDENT KINASE INHIBITORS STRANSKY NICOLAS (US) 2018-03-15 WO claimed
EP-3129470-A1 TREATMENT OF CANCER USING ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR NOVARTIS AG (CH) 2017-02-15 EP claimed
WO-2015157252-A1 TREATMENT OF CANCER USING ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR BROGDON, Jennifer (US) 2015-10-15 WO claimed
EP-2866835-A1 GPBP-1 INHIBITION AND ITS THERAPEUTIC USE Fibrostatin, S.L. (ES) 2015-05-06 EP claimed
WO-2014006020-A1 GPBP-1 INHIBITION AND ITS THERAPEUTIC USE FIBROSTATIN, S.L. (ES) 2014-01-09 WO claimed
EP-1841401-A1 REDUCTION OF HAIR GROWTH WITH SURVIVIN INHIBITORS The Gillette Company (US) 2007-10-10 EP claimed
WO-2006069192-A1 REDUCTION OF HAIR GROWTH WITH SURVIVIN INHIBITORS THE GILLETTE COMPANY (US) 2006-06-29 WO claimed
EP-1420747-A2 BENZOQUINONE ANSAMYCINS Kosan Biosciences, Inc. (US) 2004-05-26 EP claimed
WO-2003013430-A2 BENZOQUINONE ANSAMYCINS KOSAN BIOSCIENCES, INC. (US) 2003-02-20 WO claimed
EP-4234685-A2 METHODS FOR IMPROVING THE EFFICACY AND EXPANSION OF CHIMERIC ANTIGEN RECEPTOR-EXPRESSING CELLS Novartis AG (CH) 2023-08-30 EP disclosed
EP-3898626-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS INHIBITORS OF FGFR TYROSINE KINASES Array Biopharma, Inc. (US) 2021-10-27 EP disclosed
EP-3898615-A1 7-((3,5-DIMETHOXYPHENYL)AMINO)QUINOXALINE DERIVATIVES AS FGFR INHIBITORS FOR TREATING CANCER Array Biopharma, Inc. (US) 2021-10-27 EP disclosed
EP-3891294-A1 METHODS FOR TREATING CASTRATION-RESISTANT AND CASTRATION- SENSITIVE PROSTATE CANCER Sumitomo Dainippon Pharma Oncology, Inc. (US) 2021-10-13 EP disclosed
EP-3801769-A1 COMBINATION THERAPY WITH CHIMERIC ANTIGEN RECEPTOR (CAR) THERAPIES Novartis AG (CH) 2021-04-14 EP disclosed
WO-2006094029-A2 PHARMACEUTICAL FORMULATIONS CONTAINING 17-ALLYLAMINO-17-DEMETHOXYGELDANAMYCIN KOSAN BIOSCIENCES INCOPORATED (US) 2006-09-08 WO disclosed
WO-2006055472-A2 SYNTHETIC DISCODERMOLIDE ANALOGS KOSAN BIOSCIENCES INCORPORATED (US) 2006-05-26 WO disclosed
WO-2005110398-A2 PHARMACEUTICAL SOLUTION FORMULATIONS CONTAINING 17-AAG KOSAN BIOSCIENCES, INC. (US) 2005-11-24 WO disclosed
EP-1420747-A2 BENZOQUINONE ANSAMYCINS Kosan Biosciences, Inc. (US) 2004-05-26 EP disclosed
WO-2003013430-A2 BENZOQUINONE ANSAMYCINS KOSAN BIOSCIENCES, INC. (US) 2003-02-20 WO disclosed